Susan K Fried1, Karen K Miller2, Kalypso Karastergiou1, Miriam A Bredella3, Mi-Jeong Lee1, Steven R Smith4,5. 1. Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA. 2. Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA. 3. Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA. 4. Sanford/Burnham Medical Research Institute at Lake Nona, Orlando, Florida, USA. 5. Translational Research Institute for Metabolism and Diabetes, Florida Hospital, Orlando, Florida, USA.
Abstract
OBJECTIVE: Growth hormone (GH) administration reduces abdominal, but not lower body, fat mass. To gain insight into the underlying mechanisms, this study examined the expression of the GH receptor (GHR) and some of its targets in abdominal and gluteal adipose tissue. METHODS: GHR and GH targets in the lipolytic pathway were assessed (quantitative PCR/Western blotting) in adipose aspirates from premenopausal women [n = 15, age 26.9 ± 6.1 years, body mass index (BMI) 28.0 ± 6.8 kg/m(2) ] and men (n = 28, age 29.2 ± 7.0 years, BMI 26.9 ± 3.7 kg/m(2) ). RESULTS: GHR mRNA expression was lower in the gluteal depot when compared with the abdominal depot (P = 0.01). Abdominal GHR correlated negatively with age and BMI, whereas gluteal GHR was associated with lower waist-to-hip ratio (WHR), that is, pear shape. In both sites, GHR mRNA correlated strongly with genes important for the regulation of lipolysis: adipose tissue triglyceride lipase (ATGL), hormone-sensitive lipase, perilipin, and CIDEA (all P < 0.001), independently of BMI, WHR, age, and sex. GHR protein was lower in the gluteal fat when compared with the abdominal fat (P = 0.03) and correlated with ATGL protein in the gluteal depot (P < 0.001). CONCLUSIONS: GHR levels correlate with levels of lipases and lipid droplet-associated proteins crucial for lipolysis. Thus, higher GHR expression in the abdominal depot when compared with the gluteal depot may underlie the in vivo effect of GH to specifically reduce abdominal adipose tissue mass.
OBJECTIVE:Growth hormone (GH) administration reduces abdominal, but not lower body, fat mass. To gain insight into the underlying mechanisms, this study examined the expression of the GH receptor (GHR) and some of its targets in abdominal and gluteal adipose tissue. METHODS:GHR and GH targets in the lipolytic pathway were assessed (quantitative PCR/Western blotting) in adipose aspirates from premenopausal women [n = 15, age 26.9 ± 6.1 years, body mass index (BMI) 28.0 ± 6.8 kg/m(2) ] and men (n = 28, age 29.2 ± 7.0 years, BMI 26.9 ± 3.7 kg/m(2) ). RESULTS:GHR mRNA expression was lower in the gluteal depot when compared with the abdominal depot (P = 0.01). Abdominal GHR correlated negatively with age and BMI, whereas gluteal GHR was associated with lower waist-to-hip ratio (WHR), that is, pear shape. In both sites, GHR mRNA correlated strongly with genes important for the regulation of lipolysis: adipose tissue triglyceride lipase (ATGL), hormone-sensitive lipase, perilipin, and CIDEA (all P < 0.001), independently of BMI, WHR, age, and sex. GHR protein was lower in the gluteal fat when compared with the abdominal fat (P = 0.03) and correlated with ATGL protein in the gluteal depot (P < 0.001). CONCLUSIONS:GHR levels correlate with levels of lipases and lipid droplet-associated proteins crucial for lipolysis. Thus, higher GHR expression in the abdominal depot when compared with the gluteal depot may underlie the in vivo effect of GH to specifically reduce abdominal adipose tissue mass.
Authors: Miriam A Bredella; Eleanor Lin; Danielle J Brick; Anu V Gerweck; Lindsey M Harrington; Martin Torriani; Bijoy J Thomas; David A Schoenfeld; Anne Breggia; Clifford J Rosen; Linda C Hemphill; Zida Wu; Nader Rifai; Andrea L Utz; Karen K Miller Journal: Eur J Endocrinol Date: 2012-01-24 Impact factor: 6.664
Authors: Nicoleta C Olarescu; Darlene E Berryman; Lara A Householder; Ellen R Lubbers; Edward O List; Fabian Benencia; John J Kopchick; Jens Bollerslev Journal: J Endocrinol Date: 2015-05-05 Impact factor: 4.286
Authors: Miriam A Bredella; Anu V Gerweck; Eleanor Lin; Melissa G Landa; Martin Torriani; David A Schoenfeld; Linda C Hemphill; Karen K Miller Journal: J Clin Endocrinol Metab Date: 2013-07-03 Impact factor: 5.958
Authors: Kalypso Karastergiou; Susan K Fried; Hui Xie; Mi-Jeong Lee; Adeline Divoux; Marcus A Rosencrantz; R Jeffrey Chang; Steven R Smith Journal: J Clin Endocrinol Metab Date: 2012-11-12 Impact factor: 5.958
Authors: Marieke B Snijder; Jacqueline M Dekker; Marjolein Visser; Lex M Bouter; Coen D A Stehouwer; John S Yudkin; Robert J Heine; Giel Nijpels; Jacob C Seidell Journal: Diabetes Care Date: 2004-02 Impact factor: 19.112
Authors: Rita Sharma; Quyen Luong; Vishva M Sharma; Mitchell Harberson; Brian Harper; Andrew Colborn; Darlene E Berryman; Niels Jessen; Jens Otto Lunde Jørgensen; John J Kopchick; Vishwajeet Puri; Kevin Y Lee Journal: J Endocrinol Date: 2018-12-01 Impact factor: 4.286